COMPANY PROFILE

Mileutis

Mileutis focuses on creating natural peptides that can be used to manage infectious and chronic diseases without the use of antibiotics

Gan Yavne, IsraelFounded 2004Food

Valuation $100–250M Last recorded · 2020

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Mileutis

Mileutis is a specialized company based in Rehovot, Israel, focusing on the development of novel biologics and veterinary sciences. The company operates in the animal health market, targeting dairy farmers and animal health providers. Mileutis' core business involves creating biopharmaceutical products that utilize natural peptides to manage infectious and chronic diseases in animals, significantly reducing the need for antibiotics. This approach not only benefits animal health but also ensures safer products for consumers. The company's business model revolves around research and development, manufacturing, and the commercialization of these innovative therapies. Mileutis generates revenue through the sale of its patented biopharmaceutical products, which are in high demand due to their safety and efficacy. The company boasts a robust intellectual property portfolio with 52 granted patents and 10 pending applications worldwide. Mileutis' headquarters feature state-of-the-art R&D facilities, including cutting-edge laboratories and clean rooms, supporting its mission to advance animal health through science and innovation.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2004
Headquarters: Gan Yavne, Israel
Employees: 32
Open positions: None listed
Dealroom signal: 67.5/100
Industry: Food
Sub-industry: AgriTech
Sector: Food, Intellectual Property, Veterinary, Biotechnology, Chronic Disease, Hard Tech
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	May 2024	$0	—	Yotvata Dairy	↗
LATE VC✓Equity / VC	Oct 2020	$20M	$80M	NovaQuest Capital Management	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Mileutis website traffic

Latest recorded traffic for Mileutis is 1K monthly website visits, up 40.8% over the last three months. Mileutis's team declined 3% over the past year.

Latest monthly visits1K 3-month web change+40.8% 1-year team growth-3%

Monthly website visitsJun 2015–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GLGlucoMeGlucoMe’s vision is to simplify diabetes management and treatment in order to improve outcomes and reduce costs	Yarkona, Israel	Operational	1	—	—
CPCannabics PharmaceuticalsCannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform that leverages novel drug-screening tools and AI	Caesarea, Israel	Operational
ATAgribody TechnologiesEmerging ag biotech company licensing & co-developing IP covering a key genetic switch with broad applications to improve crop yields	San Diego, United States	Operational
PEPepticomAn Artificial Intelligence (AI) company for the discovery of novel molecules in the Pharmaceutical and Agricultural markets	Jerusalem, Israel	Operational
VBVero BiotechAn emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions	Atlanta, United States	Operational
TMTOM MedicationsTOM accelerates the access to a highly engaged and anonymous community of chronic patients to an unprecedented degree	Zurich, Switzerland	Operational
HIHistideBiotech intellectual property platform	Feusisberg, Switzerland	Operational
OMOmicsisIntegrative bioscience and biotechnology venture company	Daejeon, South Korea	Operational